262 related articles for article (PubMed ID: 33921111)
21. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors.
Zhang S; Yu S; Hou W; Li X; Ning C; Wu Y; Zhang F; Jiao YF; Lee LTO; Sun L
J Ovarian Res; 2019 Sep; 12(1):87. PubMed ID: 31526390
[TBL] [Abstract][Full Text] [Related]
22. Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors.
Li M; Qi SY; Wang Y; Feng SX; Zhang BZ; Wang R
Arch Gynecol Obstet; 2005 Jun; 272(1):48-52. PubMed ID: 15682318
[TBL] [Abstract][Full Text] [Related]
23. Systematic module approach identifies altered genes and pathways in four types of ovarian cancer.
Liu J; Wang HL; Ma FM; Guo HP; Fang NN; Wang SS; Li XH
Mol Med Rep; 2017 Dec; 16(6):7907-7914. PubMed ID: 28983627
[TBL] [Abstract][Full Text] [Related]
24. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.
Lu KH; Bell DA; Welch WR; Berkowitz RS; Mok SC
Cancer Res; 1998 Jun; 58(11):2328-30. PubMed ID: 9622067
[TBL] [Abstract][Full Text] [Related]
25. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study.
Hannibal CG; Frederiksen K; Vang R; Kurman RJ; Kjaer SK
Int J Cancer; 2020 Aug; 147(4):990-995. PubMed ID: 31930502
[TBL] [Abstract][Full Text] [Related]
26. Ultrasound features of different histopathological subtypes of borderline ovarian tumors.
Fruscella E; Testa AC; Ferrandina G; De Smet F; Van Holsbeke C; Scambia G; Zannoni GF; Ludovisi M; Achten R; Amant F; Vergote I; Timmerman D
Ultrasound Obstet Gynecol; 2005 Nov; 26(6):644-50. PubMed ID: 16254875
[TBL] [Abstract][Full Text] [Related]
27. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
Wamunyokoli FW; Bonome T; Lee JY; Feltmate CM; Welch WR; Radonovich M; Pise-Masison C; Brady J; Hao K; Berkowitz RS; Mok S; Birrer MJ
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):690-700. PubMed ID: 16467078
[TBL] [Abstract][Full Text] [Related]
28. Integrating the dysregulated inflammasome-based molecular functionome in the malignant transformation of endometriosis-associated ovarian carcinoma.
Chang CM; Wang ML; Lu KH; Yang YP; Juang CM; Wang PH; Hsu RJ; Yu MH; Chang CC
Oncotarget; 2018 Jan; 9(3):3704-3726. PubMed ID: 29423077
[TBL] [Abstract][Full Text] [Related]
29. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.
Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
Int J Gynecol Cancer; 2012 Jun; 22(5):770-7. PubMed ID: 22426410
[TBL] [Abstract][Full Text] [Related]
30. Serous and mucinous borderline (low malignant potential) tumors of the ovary.
Acs G
Am J Clin Pathol; 2005 Jun; 123 Suppl():S13-57. PubMed ID: 16100867
[TBL] [Abstract][Full Text] [Related]
31. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of women with a family history of ovarian cancer. I. Galactose consumption and metabolism.
Cramer DW; Muto MG; Reichardt JK; Xu H; Welch WR; Valles B; Ng WG
Cancer; 1994 Aug; 74(4):1309-17. PubMed ID: 8055453
[TBL] [Abstract][Full Text] [Related]
33. Intraoperative Diagnosis Support Tool for Serous Ovarian Tumors Based on Microarray Data Using Multicategory Machine Learning.
Park JS; Choi SB; Kim HJ; Cho NH; Kim SW; Kim YT; Nam EJ; Chung JW; Kim DW
Int J Gynecol Cancer; 2016 Jan; 26(1):104-13. PubMed ID: 26512784
[TBL] [Abstract][Full Text] [Related]
34. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors.
Alanbay I; Aktürk E; Coksuer H; Ercan CM; Karaşahin E; Dede M; Yenen MC; Ozan H; Dilek S
Eur J Gynaecol Oncol; 2012; 33(1):25-30. PubMed ID: 22439401
[TBL] [Abstract][Full Text] [Related]
35. Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors.
Elias KM; Tsantoulis P; Tille JC; Vitonis A; Doyle LA; Hornick JL; Kaya G; Barnes L; Cramer DW; Puppa G; Stuckelberger S; Hooda J; Dietrich PY; Goggins M; Kerr CL; Birrer M; Hirsch MS; Drapkin R; Labidi-Galy SI
J Pathol; 2018 Dec; 246(4):459-469. PubMed ID: 30229909
[TBL] [Abstract][Full Text] [Related]
36. Borderline Ovarian Tumors Share Familial Risks with Themselves and Invasive Cancers.
Zheng G; Yu H; Kanerva A; Försti A; Sundquist K; Hemminki K
Cancer Epidemiol Biomarkers Prev; 2018 Nov; 27(11):1358-1363. PubMed ID: 30018148
[No Abstract] [Full Text] [Related]
37. New sonographic marker of borderline ovarian tumor: microcystic pattern of papillae and solid components.
Timor-Tritsch IE; Foley CE; Brandon C; Yoon E; Ciaffarrano J; Monteagudo A; Mittal K; Boyd L
Ultrasound Obstet Gynecol; 2019 Sep; 54(3):395-402. PubMed ID: 30950132
[TBL] [Abstract][Full Text] [Related]
38. The Putative Role of
Semczuk A; Gogacz M; Semczuk-Sikora A; Jóźwik M; Rechberger T
J Cancer; 2017; 8(14):2684-2691. PubMed ID: 28928856
[TBL] [Abstract][Full Text] [Related]
39. Identifying hub genes and dysregulated pathways in hepatocellular carcinoma.
Jin B; Wang W; Du G; Huang GZ; Han LT; Tang ZY; Fan DG; Li J; Zhang SZ
Eur Rev Med Pharmacol Sci; 2015 Feb; 19(4):592-601. PubMed ID: 25753876
[TBL] [Abstract][Full Text] [Related]
40. A rat model of serous borderline ovarian tumors induced by 7,12-dimethylbenz[a]anthracene.
Cai SQ; Li Y; Li YA; Wang L; Zhu J; Zhao SH; Li X; Qiang JW
Exp Anim; 2019 Aug; 68(3):257-265. PubMed ID: 30760660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
